Biotest AG / DE0005227235
28.08.2024 - 09:00:19Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG
| Biotest AG / Key word(s): Personnel 28.08.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Dreieich, Germany, August 28, 2024. Biotest AG announced today that Dr. Jörg Schüttrumpf will in future focus on his role as Chief Scientific Innovation Officer of the entire Grifols Group. He will therefore resign from his position as Chief Scientific Officer and member of the Management Board of Biotest AG effective August 31, 2024. Biotest AG would like to take this opportunity to sincerely thank Dr. Schüttrumpf. Under his leadership, the company has achieved important milestones. The new Biotest products Fibrinogen and Trimodulin were developed, and Yimmugo® was the first product to be approved in Europe and the USA. All three products are part of the Biotest Next Level expansion program and are an important part of the Grifols Group pipeline through the technology transfer and licensing agreement. We look forward to the continued collaboration in his role within the Grifols Group. The areas of Biotest AG for which Dr. Schüttrumpf was previously responsible will in future be represented on the Management Board of Biotest AG by Mr. Janssen (CEO). About Biotest Biotest (www.biotest.com) is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com). IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406 Mail: ir@biotest.com PR contact Dirk Neumüller Phone: +49-6103-801-269 Mail: pr@biotest.com Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. 28.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Biotest AG |
| Landsteinerstraße 5 | |
| 63303 Dreieich | |
| Germany | |
| Phone: | 0 61 03 - 8 01-0 |
| Fax: | 0 61 03 - 8 01-150 |
| E-mail: | ir@biotest.com |
| Internet: | www.biotest.de |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1975987 |
| End of News | EQS News Service |
| |
